BHST logo

BIOHARVEST SCIENCES INC

BHSTNASDAQ
πŸ† #4509 by market capUS Equity
$1.30β–Ό $0.02 (βˆ’1.52%)
Market closed Β· at close
πŸ””
Track BHST
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.5%
7dβ–Ό 25.7%
14dβ–Ό 18.2%
30dβ–Ό 22.6%
ytdβ–Ό 75.6%
1yβ–Ό 78.0%
🏦Market Cap
$23M
Small Cap
πŸ“ˆRevenue Growth (YoY)
37.0%
High Growth
πŸ“ŠGross Margin
57.1%
Healthy
πŸ’΅FCF Margin
-33.0%
Thin
βš–οΈP/S Ratio
0.7x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.30 – $1.30
52-Week Range
$0.91 – $7.20
Volume (shares)
430
Avg Volume (shares)
β€”
Shares Outstanding
17.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$35M
Last Q Revenue
$9M
P/E Ratio
-2.4
P/S Ratio
0.7x
EPS (TTM)
$-0.52
Dividend Yield
0.00%
Dilution (1yr)
+6.3%
BHST logo

BIOHARVEST SCIENCES INC

BHST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$35Mβ–² +37.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.3%β–² +7.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$6Mβ–Ό βˆ’20.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$10Mβ–² +0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.4Mβ–² +6.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9Mβ–² +$20M YoY
StockOtter Β· stockotter.space

About BIOHARVEST SCIENCES INC

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Apr 2025

Latest News & Updates

News unavailable.